CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
19/04/2018 – AB Science will provide additional data through a reexamination procedure
19/04/2018 – AB Science will provide additional data through a reexamination procedure